Clinical Epidemiology Unit, Clinical Genetic Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States; Internal Medicine Residency, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, New York, United States.
Clinical Epidemiology Unit, Clinical Genetic Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.
Prev Med. 2024 Mar;180:107881. doi: 10.1016/j.ypmed.2024.107881. Epub 2024 Jan 28.
Visual assessment is currently used for primary screening or triage of screen-positive individuals in cervical cancer screening programs. Most guidelines recommend screening and triage up to at least age 65 years old. We examined cervical images from participants in three National Cancer Institute funded cervical cancer screening studies: ALTS (2864 participants recruited between 1996 to 1998) in the United States (US), NHS (7548 in 1993) in Costa Rica, and the Biopsy study (684 between 2009 to 2012) in the US. Specifically, we assessed the visibility of the squamocolumnar junction (SCJ), which is the susceptible zone for precancer/cancer by age, as reported by colposcopist reviewers either at examination or review of cervical images. The visibility of the SCJ declined substantially with age: by the late 40s the majority of people screened had at most partially visible SCJ. On longitudinal analysis, the change in SCJ visibility from visible to not visible was largest for participants from ages 40-44 in ALTS and 50-54 in NHS. Of note, in the Biopsy study, the live colposcopic exam resulted in significantly higher SCJ visibility as compared to review of static images (Weighted kappa 0.27 (95% Confidence Interval: 0.21, 0.33), Asymmetry chi-square P-value<0.001). Lack of SCJ visibility leads to increased difficulty in diagnosis and management of cervical precancers. Therefore, cervical cancer screening programs reliant on visual assessment might consider lowering the upper age limit for screening if there are not adequately trained personnel and equipment to evaluate and manage participants with inadequately visible SCJ.
目前,视觉评估用于宫颈癌筛查计划中筛查阳性个体的初步筛查或分流。大多数指南建议筛查和分流至至少 65 岁。我们检查了三个美国国立癌症研究所资助的宫颈癌筛查研究的参与者的宫颈图像:美国的 ALTS(1996 年至 1998 年期间招募的 2864 名参与者)、哥斯达黎加的 NHS(1993 年的 7548 名参与者)和美国的活检研究(2009 年至 2012 年期间的 684 名参与者)。具体来说,我们评估了宫颈图像检查或复查时阴道镜医师报告的鳞柱状交界(SCJ)的可见性,SCJ 是癌前病变/癌症的易患区。SCJ 的可见性随年龄显著下降:到 40 多岁后期,大多数接受筛查的人 SCJ 只有部分可见。在纵向分析中,从可见到不可见的 SCJ 可见性变化在 ALTS 中年龄在 40-44 岁的参与者和 NHS 中年龄在 50-54 岁的参与者中最大。值得注意的是,在活检研究中,与静态图像复查相比,活阴道镜检查导致 SCJ 可见性显著提高(加权 Kappa 0.27(95%置信区间:0.21,0.33),不对称性卡方 P 值<0.001)。SCJ 不可见导致宫颈癌前病变的诊断和管理难度增加。因此,如果没有足够的训练有素的人员和设备来评估和管理 SCJ 可见性不足的参与者,依赖视觉评估的宫颈癌筛查计划可能需要考虑降低筛查的上限年龄。